A surgical option which is minimally invasive and available as same-day outpatient procedure1,2,3 Following a positive Haute Autorité de Santé (HAS) assessment, a procedure code has been granted ...

A common New Year’s resolution is to pay more attention to your health and now there’s a new procedure to assist men to monitor a serious health issue and potentially avoid major surgery. The Lovelace ...

PLEASANTON, Calif.--(BUSINESS WIRE)--NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the presentation ...

WAYNE, Pa., July 09, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced the publication of positive results from a multi-center study reaffirming the safety and effectiveness ...

A physician with Methodist Dallas Medical Center has become the first in North Texas to help more than 125 patients with a breakthrough treatment for benign prostatic hyperplasia, or BPH. Dr. Jeffrey ...

More than 50% of men over the age of 50 suffer from benign prostatic hyperplasia, also known as an enlarged prostate. While BPH is common for older men, causing the frequent urge to urinate — ...

WAYNE, Pa.--(BUSINESS WIRE)--NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Humana, one of the ...

Pooled outcomes in more than 330 UroLift ® System subjects treated in a controlled setting were analyzed and reported by Claus Roehrborn et. al. PUL with the UroLift ® System was durable in most ...

Dear Dr. Roach: I’m 79, and for several years, I have been taking finasteride and tamsulosin for benign prostatic hyperplasia. (In the past, I underwent a TURP procedure, which I will never go through ...

PLEASANTON, Calif., Aug. 20, 2020 /PRNewswire-PRWeb/ -- NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today ...

Teleflex TFX recently announced the upcoming full market release of the Advanced Tissue Control (“ATC”) feature on its unified UroLift 2 System — a platformdesigned for the treatment of benign ...

Evidence supports the case for adopting the UroLift System for treating lower urinary tract symptoms of benign prostatic hyperplasia. The UroLift System relieves lower urinary tract symptoms, avoids ...